Xcout Intel
Pheon Therapeutics
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Subscribe to see Pheon Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Pheon Therapeutics at a glance
Pheon Therapeutics is a biotechnology company headquartered in United Kingdom. It has raised at least $188M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $120M in May 2024. Xcout tracks 8 named people at Pheon Therapeutics, including Cyrus Mozayeni (Chief Executive Officer).
Pheon Therapeutics leadership
- Cyrus MozayeniChief Executive Officer
- Arvin YangChief Medical Officer
- LEIGH ZAWELChief Scientific Officer
- Chung-Han LeeVice President, Clinical Development
- Fu LiVice President and Head of Biology
- Lawrence CripeVice President, Business Development & Corporate Strategy
2 more named people on record for Pheon Therapeutics, with roles, board committees and tenure — see the full roster →
Pheon Therapeutics funding rounds
At least $188M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $120M | 12 named | |
| Series A | $68M | 15 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Pheon Therapeutics competitors
A few of Pheon Therapeutics's closest competitors — see the full list of competitors and alternatives →
Myricx Bio is a UK biotech company headquartered in London. It specializes in the discovery and development of a novel class of selective cytotoxic payloads for Antibody-Drug Conjugates (ADCs).
PhoreMost Ltd is a Cambridge, United Kingdom-based biotechnology and drug discovery company dedicated to turning scientific breakthroughs into life-changing cancer therapies.
Alchemab Therapeutics Ltd is a biotechnology company headquartered in London, England, focused on pioneering patient-centric antibody discovery and development.
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with supplementary operations in Boston, Massachusetts. The company specializes in the development of innovative antibody-drug conjugates (ADCs) targeting various oncology indications. Its pipeline focuses on delivering best-in-class clinical treatments for patients with high unmet medical needs.
Get Pheon Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Pheon Therapeutics in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access